Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 October 2025 | Story Leonie Bolleurs | Photo Supplied
Giraffe Research Centre
The giraffe research programme and infrastructure facility at Amanzi Private Game Reserve marks the next phase in a research journey that has already placed the UFS at the forefront of giraffe science.

The University of the Free State (UFS) is taking wildlife research to new heights. On Wednesday 29 October 2025, the university will officially launch the giraffe research programme and infrastructure facility at the Amanzi Private Game Reserve near Brandfort – a first-of-its-kind in the world, dedicated to advancing local and international scientific collaboration in the study and conservation of giraffes.

The launch marks the next phase in a research journey that has already placed the UFS at the forefront of giraffe science. Over the past decade, a team of researchers, led by Prof Francois Deacon from the Department of Animal Science, has made significant contributions to understanding giraffe behaviour, physiology, and ecology. Building on pioneering work in reproductive technologies, endocrinology, anatomy, and disease, the new infrastructure combines on-site research laboratories with spacious, stress-free habitats. In this hands-on environment, veterinarians, scientists, and students can work closely with giraffes while promoting their welfare and supporting both local and international research projects.

Over the past seven years, his team has conducted 254 successful sedations and captures, carefully building the expertise needed for the next delicate step: the first embryo transfer in wild giraffes.

“This dedicated research facility will provide a safe and controlled environment where the world’s first giraffe embryo can develop and grow, and where we can collaborate to produce the science needed to turn the extinction of the giraffe around,” he explains. “The general public may not see the results immediately, but 20 years from now, what we are doing today will be vital in creating a biobank of viable giraffe embryos and calves that can be used in surrogate animals, supporting sustainable conservation practices for future generations.”

This programme will allow researchers to expand their understanding of the world’s tallest land mammal in ways that were not possible before. “From conducting sedation and sample collection to pioneering reproductive techniques such as semen preservation and embryo transfer, the facility provides an environment where we can study, among others, giraffe genetics, reproductive biology, and physiology; knowledge that is important for their conservation and survival,” says Prof Deacon. 

About 12 departments at the UFS are already involved in the research project in one way or another. This includes from the Department of Animal Science to the Departments of Zoology and Entomology, as well as Chemistry and even Information and Communication and Technology Services, which contributes to 3D-modelling, software, and monitoring of the animals. 

The project also offers opportunities for collaboration with conservation organisations and universities worldwide, positioning the UFS as a leading hub for giraffe and large-mammal research in Africa. Current partners who share Prof Deacon’s vision for giraffe conservation on the African continent include Save the Giraffes (a US-based NGO), Absolute Genetics, Ramsem, and the Kroonstad Animal Hospital.

Despite their towering presence on the African continent, giraffes are quietly disappearing. The International Union for Conservation of Nature (IUCN) lists them as Vulnerable, with populations declining by more than 40% over the past three decades. Today, fewer than 100 000 remain in the wild – a sobering reminder that their future is far from secure and that research excellence like this is key to ensure their survival.

“We have all the technology and all the expertise to make a change. Now is the time to bring about this change to secure the future of giraffes on this continent,” Prof Deacon concludes, emphasising the UFS’ commitment to sustainability, care, and conservation.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept